GSK

Business Context and Reporting Period

Company: GlaxoSmithKline plc (GSK)
Filing Type: Form 6-K (Report of Foreign Issuer)
Reporting Period: Second Quarter (Q2) and First Half (H1) ended 30 June 2012
Announcement Date: 25 July 2012

GSK reported results for a period characterized by a challenging macro-economic environment, particularly in Europe and the US, offset by growth in Emerging Markets, Asia Pacific (EMAP), and Japan. The company highlighted significant progress in its late-stage R&D pipeline, with data supporting potential launches of eight new drugs and vaccines within the next 24 months.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue: Group turnover declined 2% in Q2 and was flat in H1 on a reported basis. On a Constant Exchange Rate (CER) basis, turnover declined 2% in Q2 and was flat in H1.
  • Declines: Europe (-8% Q2, -7% H1) and US (-6% Q2, -1% H1) faced pressure from generic competition, pricing, and macro-economic conditions.
  • Growth: EMAP (+9% Q2, +6% H1) and Japan (+6% Q2, +5% H1) delivered growth. Consumer Healthcare (excluding divested brands and alli) grew 7% in both periods.
• Profitability: Core operating profit decreased 7% in Q2 and 2% in H1 (CER). Margins compressed slightly due to lower turnover and adverse mix, partially offset by cost management.
  • Non-Core Items: Total results included significant non-core items: intangible impairments (£208m Q2, £260m H1), legal costs (£197m Q2, £230m H1), and restructuring charges (£54m Q2, £135m H1). These were offset by other operating income (£309m Q2, £545m H1), primarily from asset disposals.
• Cash Flow: Adjusted free cash flow for H1 2012 was £2.062 billion, up from £1.991 billion in H1 2011, driven by better working capital performance and lower tax payments.

Guidance, Outlook, and Management Commentary

• Full Year Outlook: Management now expects full-year 2012 sales to be in line with 2011 on a constant currency basis, down from previous expectations of growth. Core operating margin is expected to be broadly in line with 2011 (32.1%).
• Dividends and Buybacks:
  • Q2 Dividend: 17p per share (+6% vs prior year).
  • Share Repurchases: Expect to spend £2.0–£2.5 billion in 2012. £1.1 billion spent YTD.
• Cost and Tax Strategy:
  • Targeting a core tax rate of 25% in 2013 (one year earlier than previously planned).
  • New manufacturing process improvements expected to generate £500 million in annual cost savings by end of 2015.
• Pipeline and Acquisitions:
  • Strong late-stage pipeline with potential for 8 new launches in 24 months (COPD, diabetes, HIV, oncology).
  • Acquisition of Human Genome Sciences (HGS) agreed for approx. $3 billion; expected to complete in Q3 2012.
• Legal Settlement: Paid £1.9 billion ($3 billion) to the US Government in July 2012 to settle long-standing investigations. This was covered by existing provisions.

Investor Verification Checklist

• Legal Settlement Impact: Verify the full terms of the £1.9 billion US government settlement and the status of the Corporate Integrity Agreement (CIA).
• Human Genome Sciences Acquisition: Confirm the completion date and integration plan for the HGS acquisition, including the commercialization of Benlysta.
• European Pricing Pressure: Assess the sustainability of the 7-8% price declines in Europe and the impact of austerity measures on vaccine sales.
• Pipeline Execution: Monitor the regulatory filing and approval status of key assets (Relvar/Breo, albiglutide, MEK/BRAF inhibitors) to validate the "8 new launches" guidance.
• alli Brand Strategy: Review the plan to rebuild the alli brand following the failed divestment and supply issues.
• Share Repurchase Pace: Track the execution of the £2.0–£2.5 billion buyback program against market conditions.